On 2025‑10‑21, Stevanato Group announced a significant expansion of its drug delivery system manufacturing capacity at its Bad Oeynhausen facility in northern Germany. The expansion adds more than 2,500 m² of advanced manufacturing space, including a new ISO 8 cleanroom.
The new space incorporates injection‑molding and automated‑assembly capabilities designed to support the production of the company’s proprietary device portfolio, including the Aidaptus autoinjector and Alina pen injector platforms.
The expansion is part of the company’s footprint‑optimization plan and strengthens its European supply‑chain integration. It enhances the company’s ability to meet growing demand for self‑injection technologies and supports global pharma and biotech partners seeking resilient, scalable solutions.
The investment demonstrates Stevanato Group’s commitment to expanding its drug‑delivery capabilities and positions the company to capture increasing market share in the self‑injection segment, reinforcing its long‑term growth strategy and competitive advantage in integrated drug containment and delivery solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.